Joachim R. Göthert

ORCID: 0000-0001-8957-6732 · 1 paper in corpus

rct 2023

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Lancet (London, England) ·doi:10.1016/s0140-6736(22)02036-0

BACKGROUND: Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and J…